Doxorubicin Completed Phase 2 Trials for Breast Cancer / Non-Hodgkin's Lymphoma (NHL) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01205503Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release